MoonLake Immunotherapeutics Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- MoonLake Immunotherapeutics price/book ratio for the quarter ending 2026-06-30 was 3.35.
- MoonLake Immunotherapeutics price/book ratio for the quarter ending 2022-06-30 was 4.36.
- MoonLake Immunotherapeutics price/book ratio for the quarter ending 2021-12-31 was -2.44, a change of -0.5 year-over-year.
- MoonLake Immunotherapeutics price/book ratio for the quarter ending 2021-09-30 was -5.91.
- MoonLake Immunotherapeutics price/book ratio for fiscal 2026 was 3.35.
- MoonLake Immunotherapeutics price/book ratio for fiscal 2022 was 4.36.
- MoonLake Immunotherapeutics price/book ratio for fiscal 2021 was -2.44, a change of -0.5 from fiscal 2020.
- MoonLake Immunotherapeutics price/book ratio for fiscal 2020 was -1.94.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |